Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459127 | 0.77 | KIF11 (0.46) | ALDH1A1KDM4EHPGD | |
| SCHEMBL6654574 | 0.76 | KMT2A (0.33) | AGBL2KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5142181 | 0.76 | KMT2A (0.33) | AGBL2KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL28713868 | 0.74 | NOS3 (0.36) | KMT2ASMN1; SMN2ALDH1A1KDM4EPOLB | |
| SCHEMBL790734 | 0.74 | ALDH1A1 (0.40) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL28887006 | 0.74 | KIF11 (0.33) | AGBL2KMT2APOLB | |
| SCHEMBL21810854 | 0.74 | SMN1; SMN2 (0.37) | AGBL2KMT2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL932697 | 0.70 | — | — | |
| SCHEMBL8894256 | 0.69 | AGBL2 (0.41) | AGBL2KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL193940 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615917-A2 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS III | BASF SE (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130180014-A1 | Pyridine Compounds for Controlling Invertebrate Pests III | BASF SE (DE) | 2013-07-11 | — | — | US | disclosed |
| WO-2012034959-A2 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS III | BASF SE (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130180014-A1 | Pyridine Compounds for Controlling Invertebrate Pests III | CHRM1, CHRM2, GRIN2C | AGBL2 4165/4885KMT2A 1030/4885SMN1; SMN2 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.